Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program
05. Oktober 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere™ (meropenem and vaborbactam)
02. Oktober 2018 08:00 ET
|
Melinta Therapeutics
Vabomere monotherapy was associated with increased clinical cure, decreased mortality, and was well tolerated compared to best available therapy (BAT) -Data used by CMS in decision to grant a new...
Melinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries
01. Oktober 2018 08:15 ET
|
Melinta Therapeutics
- Total consideration of up to $265 million (including potential royalties) -- Expands on existing commercial and co-development agreement for Baxdela® (delafloxacin) - NEW HAVEN, Conn. and FLORENCE,...
Melinta Therapeutics to Present at Upcoming Investor Conferences
25. September 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics to Give New Presentations on Antibiotics Portfolio and Pipeline at IDWeek™ 2018
24. September 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam)
21. September 2018 07:37 ET
|
Melinta Therapeutics
Recommended to be approved for treatment of: Complicated intra-abdominal (cIAI) and urinary tract infections (cUTI) -Hospital-acquired pneumonia including ventilator associated pneumonia...
Melinta Therapeutics Names Peter Milligan as Chief Financial Officer
18. September 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference
06. September 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
29. August 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics Reports Second Quarter 2018 Financial Results
07. August 2018 07:00 ET
|
Melinta Therapeutics
Solid Performance from New Product Launches VabomereTM Granted NTAP Status by CMS Strengthened Financial Position Supports Continued Growth Completed Expansion and Cross-Training of Experienced...